NewLimit

Radically extending human healthspan

[NewLimit @newlimit]

Following breakthrough results, we’re bringing longevity medicine to human trials.

We’ve raised a $435M Series C led by @foundersfund to make it happen.

Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.

[Blake Byers @byersblake]

Over the summer, we achieved more drug development milestones than in the rest of @newlimit history. We scaled our manufacturing processes, ran our first large animal model studies, and engaged productively with regulators. Our pipeline of reprogramming payloads continued to grow, hitting new all time highs for both the quality of our best payloads and the quantity of payloads we explored.

>2X stronger regenerative rescue in old hepatocytes

+2 payloads rescue multiple functions in old hepatocytes

+8 payloads restore function in old endothelial cells, +5 in hepatocytes

314X scale up of therapeutic manufacturing, 13X quality improvement

2.5X improvement in endothelial cell age prediction accuracy

>5000 payloads tested (during just the summer) for effects on cell age (all time high!)

5X improvement in data efficiency from transfer learning

[Jacob Kimmel @jacobkimmel]

summer @newlimit: we found our best age reprogramming payloads yet, hit more drug dev milestones than ever before, & welcomed new leaders to the team.

it's the most exciting time in our history & we hope you consider joining us.

highlights

- >2X increase in regenerative restoration in old hepatocytes
- +8 payloads restore endothelial function, +5 in hepatocytes
- >300X scale up of therapeutic manufacturing, 13X quality improvement
- 5X increase in sample efficiency for reprogramming AI

[Brian Armstrong @brian_armstrong]

All warfare is based on deception. I actually got first place on the healthmaxxing benchmark.

Don't worry though Will, the other company I co-founded is developing drugs to rejuvenate your liver, so I got you.

[Jacob Kimmel @jacobkimmel]

.@newlimit is hosting a dinner in boston on sept 24 to connect with talented scientists & engineers

we promise an evening of surprising conversations, good food, & better company

let us know if you or a friend are interested in joining!

https://t.co/1gFw9BKo2b

[MTS @MTSlive]

NewLimit CEO @jacobkimmel explains the clinical trial bottleneck AI can't fix: biology has irreducible latency

"It's unlikely we're gonna see rapid expedition of clinical trials because a lot of the periods of time can't be expedited based on the biological primitives. In computer science you often have a notion of bandwidth and latency."

"There are some irreducible latencies in clinical trials. If you wanna give a drug to a patient and see if they're healthy a month later, it's not like you can enroll 30 patients and check back in one day. You just need to wait a full month. The classic nine people can't have a baby in one month story."

"The other thing we can hope for is that the success rate might improve. Right now, rough math, roughly 9 out of 10 drugs that go into the clinic will ultimately fail."

"If you're able to even just 2X that success rate, getting to 20% success rather than 10%, then you would double the number of drugs that come out every year, and you would cut the effective cost in half."
@newlimit

[The Techno Optimist @technooptimist1]

.@newlimit CEO @jacobkimmel on why AI is biotech's biggest shift in 40+ years:

"I really do think artificial intelligence in biopharma is the first revolution we've seen since recombinant DNA of the same scale.

It's the first technology disruption on the same order of magnitude.

And I think what we're going to see is some of these firms that are developing models that help us design molecules, partner with pharmas to develop those molecules and make medicines that just couldn't have existed before."

— Jacob Kimmel, Co-Founder and CEO of NewLimit, on @corememory

[Brian Armstrong @brian_armstrong]

The two best longevity drugs on the market currently are exercise and sleep. And they're free!

If @newlimit is successful, we might surpass those.

[Jacob Kimmel @jacobkimmel]

first-in-history data arrived @newlimit today

small piece of a note to our team. we are so lucky to be living in this future.

[Jacob Kimmel @jacobkimmel]

enjoyed chatting with @SabrinaHalper in the lab (!) a few weeks back

rarely do i get to cover whale lifespans, @newlimit, spacefaring human speciation events, & ai therapeutic design in one place

[Jacob Kimmel @jacobkimmel]

this is our most dynamic summer yet @newlimit

- 3X data efficiency for reprogramming AI from lineage generalization
- >100X manufacturing scale for our lead therapeutic asset
- +4 leads that restore function in old hepatocytes, +5 payloads in endothelium

& lots more in our blog

[Brian Armstrong @brian_armstrong]

NewLimit made major progress in the past year toward our mission of radically extending human healthspan.

Check out this talk where we run through what we've built, and our vision for where it's going.

[Jacob Kimmel @jacobkimmel]

every year @newlimit, we host friends at the lab & share our progress

for 2026, we announced:

- 2X increase in discovery rates with AI systems
- new program for endothelial cells
- 0 -> 1 medicines headed to the clinic
- accelerating recovery from alcohol

some highlights --

[Jacob Kimmel @jacobkimmel]

in our 2026 @newlimit progress update, we announced our first candidate medicine.

it has the one of the most striking effects i’ve ever seen.

a single treatment accelerates recovery from alcohol in old animals. it’s so dramatic you can see it with your bare eyes!

[NewLimit @newlimit]

Each year, we share a public update on our progress @newlimit from our lab in South San Francisco.

This year, we announced:

1. 2X increase in discovery rates with AI systems
2. New program focused on endothelial cells
3. 0 -> 1 medicines headed to the clinic

Full event video below

[Brian Armstrong @brian_armstrong]

Imagine you had the energy, metabolism, and mental agility of your younger self - without the aches and pains that come from aging.

That’s what we’re attempting to build at @NewLimit and it will be one of the most important achievements in human history ever if it works.

We're on the cusp of this being tractable given the rise of AI to test more hypotheses in-silico, along with the rapidly falling cost of single cell sequencing, etc.

We announced our Series C and upcoming human clinical trials this week, so still a long, long way to go, with many risks. But with hard work we've got a shot at making this a reality.

[Ashlee Vance @ashleevance]

New Limit just raised $435 million. This is, in part, because they've had a massive breakthrough on reversing the age of the liver with their new brand of genetic reprogramming drugs.

For the first time, NewLimit's co-founder and president Jacob Kimmel details the company's breakthrough here.

We also get into the longevity and bio-tech fields more broadly to explain where aging science and AI are heading.

If nothing else, come to see some mice get drunk.

The Core Memory podcast is available wherever you pod, and I'll put the YouTube link down below in the replies.

Our show is sponsored by Brex and SendCutSend. They are both wise and benevolent.

Timestamps
0:00 Intro
3:50 What Is Epigenetic Reprogramming?
7:16 Growing a Whole Animal From One Old Cell
13:06 Meet Ambrosia, the AI Hunting for Youth
22:44 $435 Million and the Race to Human Trials
29:26 The Drunk Mice That Skip the Hangover
36:48 Inside the First Human Trial
43:14 Will There Ever Be a Hangover Pen?
49:39 Beyond the Liver: The Delivery Problem
1:03:27 Answering the Skeptics
1:12:42 Will OpenAI Become a Drug Company?
1:23:53 The Health Story Bigger Than AI?
1:35:00 How Far Behind Is the US vs China?
1:53:10 Can We Build Computers From Neurons?

[Ashlee Vance @ashleevance]

Your reminder that we have a glorious video taking a look inside @newlimit's labs. https://t.co/jeX59XAHly

[Andrew Dunn @AndrewE_Dunn]

NewLimit, the anti-aging startup co-founded by Coinbase CEO Brian Armstrong, has closed the 2nd largest round in biotech for 2026: https://t.co/NBjbMOH8bX

[Patrick Hsu @pdhsu]

Human trials next year for @newlimit's first aging reprogramming medicine with an exciting pipeline behind it. An honor to be a partner to @jacobkimmel @byersblake @brian_armstrong and NewLimit's stellar scientists

[Ilya Fushman @ilyaf]

Congratulations @byersblake @jacobkimmel @brian_armstrong and the entire @newlimit team!